Next Biomed Overview

  • Founded
  • 1999
Founded
  • Status
  • Private
  • Employees
  • 5
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $207K
Latest Deal Amount
  • Investors
  • 2

Next Biomed General Information

Description

Developer of scaffold protein technologies designed to offer polypeptides from antibody fragments. The company's technologies develop recombinant binder proteins and offer diagnostic services based on multi-functional recombinant polypeptides that can outperform monoclonal antibodies in diagnostic applications, enabling healthcare professionals to perform research on advanced medicines and develop treatments for diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Primary Office
  • Viikinkaari 6
  • 00790 Helsinki
  • Finland
+358 09 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Next Biomed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 05-Nov-2015 $207K 00000 00000 Completed Startup
To view Next Biomed’s complete valuation and funding history, request access »

Next Biomed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000 0000.00 0000.00 00 0000.00 00.000
Ordinary 0,000 0000.00 0000.00 00 0000.00 00.000
To view Next Biomed’s complete cap table history, request access »

Next Biomed Executive Team (4)

Name Title Board Seat Contact Info
Anna Mäkelä Ph.D Head, Research & Development
Paul Partanen Owner
Kalle Saksela MD Chief Executive Officer, Board Member & Chief Scientific Officer
You’re viewing 3 of 4 executive team members. Get the full list »

Next Biomed Board Members (5)

Name Representing Role Since
Dennis Bamford Ph.D Self Board Observer 000 0000
Eero Makkonen Self Chairman 000 0000
Hans-Georg Kräusslich Ph.D Self Board Observer 000 0000
Heikki Miettinen Innofinance Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Next Biomed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Next Biomed Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innofinance Venture Capital Minority 000 0000 000000 0
Security Trading Corporation Minority 000 0000 000000 0
To view Next Biomed’s complete investors history, request access »